Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
3.
Z Rheumatol ; 80(2): 189-193, 2021 Mar.
Artículo en Alemán | MEDLINE | ID: mdl-33236165

RESUMEN

Subacute cutaneous lupus erythematosus (SCLE) is a subtype of cutaneous lupus erythematosus characterized by high photosensitivity, the occurrence of annular or papulosquamous skin lesions located in body regions exposed to UV light, the presence of anti-Ro/SS­A antibodies, and mild systemic involvement, such as arthralgia and myalgia. Similar to other subtypes of cutaneous lupus erythematosus, certain trigger factors exist for the development of SCLE, such as exposure to UV light, cigarette smoking and drugs. Rheumatic diseases, such as dermatomyositis, have been known as paraneoplastic syndromes for a long time. In recent years, there has been an accumulation of publications on the association of SCLE with malignant diseases. This article reports the case of a 78-year-old female patient who was diagnosed with the concomitant development of SCLE and gastric carcinoma. In all older patients with SCLE, patients with widespread skin affection outside the UV-exposed body areas or patients with B­symptoms, the presence of a paraneoplastic SCLE should be considered and appropriate diagnostic steps should be initiated to screen for an associated neoplastic disease.


Asunto(s)
Lupus Eritematoso Cutáneo , Síndromes Paraneoplásicos , Enfermedades Reumáticas , Anciano , Autoanticuerpos , Femenino , Humanos , Lupus Eritematoso Cutáneo/diagnóstico , Síndromes Paraneoplásicos/diagnóstico , Piel
4.
Internist (Berl) ; 61(6): 621-625, 2020 Jun.
Artículo en Alemán | MEDLINE | ID: mdl-32367302

RESUMEN

A patient with diffuse angiokeratomas of the lower abdomen and genital region was diagnosed with Fabry disease on the basis of genetic testing. Fabry disease is an X-linked lysosomal storage disease that can affect several organ systems including the heart or kidneys, resulting in reduced median survival. Pathogenetically, Fabry disease leads to a deficiency of the lysosomal enzyme α­galactosidase A (α-GAL A). Treatment options include lifelong enzyme replacement therapy or chaperone therapy.


Asunto(s)
Terapia de Reemplazo Enzimático , Enfermedad de Fabry/diagnóstico , Enfermedad de Fabry/terapia , Abdomen , Adulto , Angioqueratoma/patología , Enfermedad de Fabry/genética , Genitales , Glicoesfingolípidos/sangre , Humanos , Masculino , Neoplasias Cutáneas/patología , alfa-Galactosidasa/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA